TESARO, Inc., an oncology-focused biopharmaceutical company, announced that VARUBI™ (rolapitant), an NK-1 receptor antagonist, is now available in the United States. The U.S. Food and Drug Administration (FDA) approved VARUBI on Sept. 1, 2015, for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
The European Commission (EC) has granted orphan drug designation to Retrophin Inc's sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).
Meridian Bioscience, Inc. announced it has received clearance from the U.S. Food and Drug Administration (FDA) for new claims for its illumigene® Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab™ (Copan Diagnostics, Inc.).
ESwab is a multipurpose universal transport system that a significant portion of laboratories in the United States currently use to streamline workflows and eliminate costs associated with stocking multiple swab types.
BioSyent Inc. ("BioSyent") announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of CYSVIEW®, a new photosensitizer for the detection and management of papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
The IIHMR University is a specialized Research University in management research, postgraduate education and training exclusively in the health sector. The university is ranked No. 1 B-School (Health Sector) in Outlook 2014, 2013, 2012, 2011 and No. 1 Institute in Healthcare Management in Hindustan Times. The University has been designated as WHO collaborating Center for District Health Systems based on Primary Health Care.
